A common phenotype associated with atherogenesis in diverse mouse models of vascular lipid lesions

Journal of Vascular Research

Volumn 38, Issue 3, 2001, Pages 256-265

  Reckless, Jill ^a,c   Rubin, Edward M ^b   Verstuyft, Judy B ^b   Metcalfe, James C ^a   Grainger, David J ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Arteries; Atherosclerosis; Cytokines; Macrophages; Quantitative immunofluorescence

Indexed keywords

CD11B ANTIGEN; LIPID; OSTEOPONTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; DNA MODIFICATION; IMMUNOFLUORESCENCE; LIPOPROTEIN METABOLISM; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR LESION;

ANIMALS; APOLIPOPROTEINS; APOLIPOPROTEINS A; APOLIPOPROTEINS B; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MONOCYTES; OSTEOPONTIN; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIALOGLYCOPROTEINS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0034950295     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051054     Document Type: Article

References (53)

1. Cell biology of atherosclerosis
2. The pathogenesis of atherosclerosis - A perspective for the 1990's
3. Mouse models of atherosclerosis
4. Transgenic mouse models of lipoprotein metabolism and atherosclerosis
5. Atherogenesis - Insights from the study of transgenic and gene targeted mice
6. Tamoxifen elevates transforming growth factor beta and suppresses diet-induced formation of lipid lesions in mouse aorta
7. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice
8. Increased type-1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
9. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries
10. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease
11. Elevated levels of plasminogen activator inhibitor type-1 in atherosclerotic aorta
12. Significance of raised plasma concentrations of tissue-plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease
13. Transforming growth factor beta in inflammation: A cause and a cure
14. Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells
15. Mediation of cardioprotection by transforming growth factor-beta
16. Transforming growth factor-beta inhibits human vascular smooth muscle cell growth and migration
17. Targeted disruption of the mouse transforming growth factor beta-1 gene results in multifocal inflammatory disease
18. Transforming growth factor-beta 1 null mice. An animal model for inflammatory disorders
19. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity
20. Calcification of vascular smooth muscle cell cultures: Inhibition by osteopontin
21. Vascular calcification: New insights into an old problem
22. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI
23. Human apolipoprotein AI prevents atherosclerosis associated with apolipoprotein(a) in transgenic mice
24. Atherogenesis in transgenic mice expressing human apolipoprotein(a)
25. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice
26. Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice
27. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a)
28. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E deficient mice created by homologous recombination in ES cells
29. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E
30. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells
31. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses
32. Quantitative assessment of atherosclerotic lesions in mice
33. Optimization of immunofluorescence methods by quantitative image analysis
34. MCP-1 but not TNF-α is correlated with monocyte infiltration in mouse lipid lesions
35. Tamoxifen decreases cholesterol seven-fold and abolishes lipid lesion development in apolipoprotein E knockout mice
36. Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells
37. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques
38. Osteopontin expression in platelet-derived growth factor-stimulated vascular smooth muscle cells and carotid artery after balloon angioplasty
39. Synthesis of TNF-α and TGF-β mRNA in the different micro-environments within atheromatous plaques
40. Expression of transforming growth factor β-1 is increased in human vascular restenosis lesions
41. Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines
42. Mechanism of activation of latent recombinant TGF-β1 by plasmin
43. Characterization of the activation of latent TGF-β by co-cultures of endothelial cells and pericytes or smooth muscle cells: A self-regulating system
44. Thrombospondin-1 does not activate TGF-β in a chemically defined system or in smooth muscle cell cultures
45. Transforming growth factor-β dynamically regulates vascular smooth muscle differentiation in vivo
46. Early onset multifocal inflammation in the TGF-β1 null mouse is lymphocyte mediated
47. Dietary fat and reduced levels of TGF-β1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions
48. Increased PAI activity and PAI-1 antigen occurring with an oral fat load: Associations with PAI-1 genotype and plasma active TGF-β levels
49. TGF-β in blood: A complex problem
50. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice
51. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial
52. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen
53. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression